Basic Information
| RNALocate ID: | RLID:11001039 |
| RNA Symbol: | hsa-miR-106a-5p |
| Localization: | Exosome |
RNA Information
| RNA Name: | hsa-miR-106a-5p |
| RNA ID: | miRBase:MIMAT0000103 |
| RNA Category: | miRNA |
| Species: | Homo sapiens |
Localization Information
| PubMed ID: | 23382797 |
| Tissue/Cell Line: | Brain tissue |
| Method: | Microarray |
| Description: | We performed miRNA expression analysis using a FlexMAP3D instrument by (Luminex Corporation, Austin, TX) and a manufacturer's assay for 312 miRNA (Table S1). Data are collected from Table S1. |
Other Subcellular Localization
| RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
| RLID:01001467 | Cytoplasm | Nasopharyngeal carcinoma cells | 20498841 |
| RLID:01001468 | Cytoplasm | Neural progenitor cells | 21363885 |
| RLID:01001469 | Cytoplasm | Cell line (HeLa) | 21695135 |
| RLID:01001470 | Cytoplasm | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:01001471 | Mitochondrion | Myotube | 27396686 |
| RLID:01001472 | Mitochondrion | Skeletal muscle cells | 27563705 |
| RLID:01001473 | Mitochondrion | Skeletal muscle myoblasts | 21637849 |
| RLID:01001474 | Mitochondrion | Cell line (HEK-293|HeLa) | 22984580 |
| RLID:01001475 | Nucleus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:01001476 | Nucleolus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:01001477 | Nucleus | Nasopharyngeal carcinoma cells | 20498841 |
| RLID:11001035 | Apoptotic body | Human umbilical vein endothelial cells | 19996457 |
| RLID:11001036 | Exosome | Sera | 24978137 |
| RLID:11001037 | Exosome | Plasma | 19289371 |
| RLID:11001038 | Exosome | Breast milk | 22211110 |
| RLID:11001040 | Exosome | Plasma | 23663360 |
| RLID:11001041 | Exosome | Human mast cell line (HMC-1) | 24009880 |
| RLID:11001042 | Exosome | Colon cancer cell line (LIM1863) | 25330373 |
| RLID:11001043 | Exosome | Serum | 25349172 |
| RLID:11001044 | Microvesicle | Seminal plasma | 23539611 |
| RLID:11001045 | Microvesicle | Follicular fluid | 23666971 |
| RLID-D:11000302 | Microvesicle | Fibroblasts|Mesenchymal stem cells | |
| RLID-D:11001161 | Exosome | Breast milk|Cell lines|Epididymal epithelial cells|Osteoblast|Plasma|Primary glioblastoma neurosphere cells|Primary keratinocyte|Saliva|Serum|Urine |
ncRNA Disease Information
| Resource | RNA Symbol | Disease | Link |
| MNDR | hsa-miR-106a-5p | Diffuse large b cell lymphoma | MNDR-E-MI-03360 |
| MNDR | hsa-miR-106a-5p | Splenic marginal zone lymphoma | MNDR-E-MI-03361 |
| MNDR | hsa-miR-106a-5p | Multiple sclerosis chronic progressive | MNDR-E-MI-03362 |
| MNDR | hsa-miR-106a-5p | Oral squamous cell carcinoma | MNDR-E-MI-03363 |
| MNDR | hsa-miR-106a-5p | Follicular cleaved lymphoma | MNDR-E-MI-03364 |
| MNDR | hsa-miR-106a-5p | Medulloblastoma | MNDR-E-MI-03365 |
| MNDR | hsa-miR-106a-5p | Small intestinal neuroendocrine tumor | MNDR-E-MI-03366 |
| MNDR | hsa-miR-106a-5p | High-grade serous ovarian carcinoma | MNDR-E-MI-03367 |
| MNDR | hsa-miR-106a-5p | Ovarian clear cell carcinoma | MNDR-E-MI-03368 |
| MNDR | hsa-miR-106a-5p | Uterine corpus endometrial carcinoma | MNDR-E-MI-03369 |
| MNDR | hsa-miR-106a-5p | Lymphoma | MNDR-E-MI-03370 |
| MNDR | hsa-miR-106a-5p | Lymphoma non-hodgkin | MNDR-E-MI-03371 |
| MNDR | hsa-miR-106a-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-03372 |
| MNDR | hsa-miR-106a-5p | Estrogen-receptor negative breast cancer | MNDR-E-MI-03373 |
| MNDR | hsa-miR-106a-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-03374 |
| MNDR | hsa-miR-106a-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-03375 |
| MNDR | hsa-miR-106a-5p | Her2-receptor positive breast cancer | MNDR-E-MI-03376 |
| MNDR | hsa-miR-106a-5p | Breast cancer luminal | MNDR-E-MI-03377 |
| MNDR | hsa-miR-106a-5p | Precursor cell lymphoblastic leukemia-lymphoma | MNDR-E-MI-03378 |
| MNDR | hsa-miR-106a-5p | B cell acute lymphoblastic leukemia | MNDR-E-MI-03379 |
| MNDR | hsa-miR-106a-5p | Small intestine cancer | MNDR-E-MI-03380 |
| MNDR | hsa-miR-106a-5p | Prostate cancer | MNDR-E-MI-03381 |
| MNDR | hsa-miR-106a-5p | Gastric cancer | MNDR-E-MI-03382 |
| MNDR | hsa-miR-106a-5p | Gastric lymphoma | MNDR-E-MI-03383 |
| MNDR | hsa-miR-106a-5p | Alzheimer disease | MNDR-E-MI-03384 |
| MNDR | hsa-miR-106a-5p | Dysautonomia familial | MNDR-E-MI-03385 |
| MNDR | hsa-miR-106a-5p | Leukemia | MNDR-E-MI-03386 |
| MNDR | hsa-miR-106a-5p | Huntington disease | MNDR-E-MI-03387 |
| MNDR | hsa-miR-106a-5p | Chorea | MNDR-E-MI-03388 |
| MNDR | hsa-miR-106a-5p | Carotid stenosis | MNDR-E-MI-03389 |
| MNDR | hsa-miR-106a-5p | Lung cancer | MNDR-E-MI-03390 |
| MNDR | hsa-miR-106a-5p | Fragile x syndrome | MNDR-E-MI-03391 |
| MNDR | hsa-miR-106a-5p | Parkinson disease | MNDR-E-MI-03392 |
| MNDR | hsa-miR-106a-5p | Basal-like breast cancer | MNDR-E-MI-03393 |
| MNDR | hsa-miR-106a-5p | Pancreatic cancer | MNDR-E-MI-03394 |
| MNDR | hsa-miR-106a-5p | Melanoma | MNDR-E-MI-03395 |
| MNDR | hsa-miR-106a-5p | Lesch-nyhan syndrome | MNDR-E-MI-03396 |
| MNDR | hsa-miR-106a-5p | Rectum adenocarcinoma | MNDR-E-MI-03397 |
| MNDR | hsa-miR-106a-5p | Hepatitis B | MNDR-E-MI-03398 |
| MNDR | hsa-miR-106a-5p | Epithelial ovarian cancer | MNDR-E-MI-03399 |
| MNDR | hsa-miR-106a-5p | Nephroblastoma | MNDR-E-MI-03400 |
| MNDR | hsa-miR-106a-5p | Colon cancer | MNDR-E-MI-03401 |
| MNDR | hsa-miR-106a-5p | Ischemic attack transient | MNDR-E-MI-03402 |
| MNDR | hsa-miR-106a-5p | Colon adenocarcinoma | MNDR-E-MI-03403 |
| MNDR | hsa-miR-106a-5p | Multiple sclerosis | MNDR-E-MI-03404 |
| MNDR | hsa-miR-106a-5p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-03405 |
| MNDR | hsa-miR-106a-5p | Familial ovarian cancer | MNDR-E-MI-03406 |
| MNDR | hsa-miR-106a-5p | Prostate adenocarcinoma | MNDR-E-MI-03407 |
| MNDR | hsa-miR-106a-5p | Kidney cancer | MNDR-E-MI-03408 |
| MNDR | hsa-miR-106a-5p | Carcinoma ductal breast | MNDR-E-MI-03409 |
| MNDR | hsa-miR-106a-5p | Glioblastoma | MNDR-E-MI-03410 |
| MNDR | hsa-miR-106a-5p | Astrocytoma | MNDR-E-MI-03411 |
| MNDR | hsa-miR-106a-5p | Glioma | MNDR-E-MI-03412 |
| MNDR | hsa-miR-106a-5p | Amyotrophic lateral sclerosis | MNDR-E-MI-03413 |
| MNDR | hsa-miR-106a-5p | Epilepsy temporal lobe | MNDR-E-MI-03414 |
| MNDR | hsa-miR-106a-5p | Osteosarcoma | MNDR-E-MI-03415 |
| MNDR | hsa-miR-106a-5p | Liposarcoma | MNDR-E-MI-03416 |
| MNDR | hsa-miR-106a-5p | Meningioma | MNDR-E-MI-03417 |
| MNDR | hsa-miR-106a-5p | Liver cancer | MNDR-E-MI-03418 |
| MNDR | hsa-miR-106a-5p | Cervical adenocarcinoma | MNDR-E-MI-03419 |
| MNDR | hsa-miR-106a-5p | Gastric adenocarcinoma | MNDR-E-MI-03420 |
| MNDR | hsa-miR-106a-5p | Cervical squamous cell carcinoma | MNDR-E-MI-03421 |
| MNDR | hsa-miR-106a-5p | Lung squamous cell carcinoma | MNDR-E-MI-03422 |
| MNDR | hsa-miR-106a-5p | Carcinoma lung non-small-cell | MNDR-E-MI-03423 |
| MNDR | hsa-miR-106a-5p | Lung adenocarcinoma | MNDR-E-MI-03424 |
| MNDR | hsa-miR-106a-5p | Thyroid carcinoma | MNDR-E-MI-03425 |
| MNDR | hsa-miR-106a-5p | Ovarian carcinoma | MNDR-E-MI-03426 |
| MNDR | hsa-miR-106a-5p | Bladder urothelial carcinoma | MNDR-E-MI-03427 |
| MNDR | hsa-miR-106a-5p | Pancreatic adenocarcinoma | MNDR-E-MI-03428 |
| MNDR | hsa-miR-106a-5p | Carcinoma renal cell | MNDR-E-MI-03429 |
| MNDR | hsa-miR-106a-5p | Papillary renal cell carcinoma | MNDR-E-MI-03430 |
| MNDR | hsa-miR-106a-5p | Clear cell renal cell cancer | MNDR-E-MI-03431 |
| MNDR | hsa-miR-106a-5p | Biliary tract cancer | MNDR-E-MI-03432 |
| MNDR | hsa-miR-106a-5p | Cholangiocarcinoma | MNDR-E-MI-03433 |
| MNDR | hsa-miR-106a-5p | Esophageal cancer | MNDR-E-MI-03434 |
| MNDR | hsa-miR-106a-5p | Lung small cell carcinoma | MNDR-E-MI-03435 |
| MNDR | hsa-miR-106a-5p | Head and neck squamous cell carcinoma | MNDR-E-MI-03436 |
| MNDR | hsa-miR-106a-5p | Testicular germ cell cancer | MNDR-E-MI-03437 |
| MNDR | hsa-miR-106a-5p | T acute lymphoblastic leukemia | MNDR-E-MI-03438 |
| MNDR | hsa-miR-106a-5p | Acute t cell leukemia | MNDR-E-MI-03439 |
| MNDR | hsa-miR-106a-5p | Acute heart failure | MNDR-E-MI-03440 |
| MNDR | hsa-miR-106a-5p | Aortic valve disease | MNDR-E-MI-03441 |
| MNDR | hsa-miR-106a-5p | Adenoma | MNDR-E-MI-03442 |
| MNDR | hsa-miR-106a-5p | Breast invasive carcinoma | MNDR-E-MI-03443 |
| MNDR | hsa-miR-106a-5p | Hepatocellular carcinoma | MNDR-E-MI-03444 |
| MNDR | hsa-miR-106a-5p | Embryonal cancer | MNDR-E-MI-03445 |
| MNDR | hsa-miR-106a-5p | Familiar ovarian carcinoma | MNDR-E-MI-03446 |
| MNDR | hsa-miR-106a-5p | B-cell lymphoma | MNDR-E-MI-03447 |
| MNDR | hsa-miR-106a-5p | T-cell leukemia | MNDR-E-MI-03448 |
| MNDR | hsa-miR-106a-5p | Neuroblastoma | MNDR-E-MI-03449 |
| MNDR | hsa-miR-106a-5p | Burkitt lymphoma | MNDR-E-MI-03450 |
| MNDR | hsa-miR-106a-5p | Psoriasis | MNDR-E-MI-03451 |
| MNDR | hsa-miR-106a-5p | Acute myelocytic leukemia | MNDR-E-MI-03452 |
| MNDR | hsa-miR-106a-5p | Colorectal cancer | MNDR-E-MI-03453 |
| MNDR | hsa-miR-106a-5p | Multiple myeloma | MNDR-E-MI-03454 |
| MNDR | hsa-miR-106a-5p | Ependymoma | MNDR-E-MI-03455 |
| MNDR | hsa-miR-106a-5p | Prostatic neoplasms | MNDR-E-MI-03456 |
| MNDR | hsa-miR-106a-5p | Pseudorabies | MNDR-E-MI-03457 |
| MNDR | hsa-miR-106a-5p | Hypersomnolence idiopathic | MNDR-E-MI-03458 |
| MNDR | hsa-miR-106a-5p | Arsenic poisoning | MNDR-E-MI-03459 |
| MNDR | hsa-miR-106a-5p | Stroke lacunar | MNDR-E-MI-03460 |
| MNDR | hsa-miR-106a-5p | Duke C | MNDR-E-MI-03461 |
RNA Interaction Information
| Resource | RNA Symbol | Species | Link | RNALocate ID |
| RNAInter | ABHD2 | Homo sapiens | RR00026071 |
TOP